Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials

被引:8
|
作者
Bavishi, Chirag [1 ]
Chugh, Yashasvi [2 ,3 ]
Kimura, Takeshi [4 ]
Natsuaki, Masahiro [5 ]
Kaiser, Christoph [6 ]
Gordon, Paul [1 ]
Aronow, Herbert D. [1 ]
Abbott, Jinnette Dawn [1 ]
机构
[1] Rhode Isl Hosp, Lifespan Cardiovasc Inst, Providence, RI 02903 USA
[2] Mt Sinai St Lukes Hosp, New York, NY USA
[3] Mt Sinai West Hosp, New York, NY USA
[4] Kyoto Univ, Grad Sch Med, Sakyo Ku, Kyoto, Japan
[5] Saga Univ, Saga, Japan
[6] Univ Hosp, Basel, Switzerland
关键词
Biodegradable polymer; Durable polymer; Drug-eluting stent; Diabetes; EVEROLIMUS; SAFETY; THROMBOSIS; OUTCOMES; EFFICACY; LEADERS;
D O I
10.1093/ehjqcco/qcz031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The biodegradable polymer drug-eluting stents (BP-DES) offer controlled drug elution and complete degradation of the polymer over time, eventually lowering the risk for chronic inflammation and neoatherosclerosis, which can be particularly helpful in patients with diabetes. While BP-DES and durable polymer drug-eluting stents (DP-DES) have demonstrated comparable efficacy in all-comers population, their efficacy and safety in patients with diabetes remains uncertain. Methods and results Electronic databases were systematically searched for randomized controlled trials (RCTs) comparing BP-DES with contemporary DP-DES in patients with diabetes. Study investigators were contacted to obtain additional data. The primary outcome was efficacy in terms of target-vessel revascularization (TVR) and target-lesion revascularization (TLR). We also evaluated the following safety outcomes separately: all-cause mortality, cardiac mortality, myocardial infarction (MI), and definite or probable stent thrombosis. Eleven RCTs including 5190 diabetic patients were included. At the longest available follow-up (mean 2.7 years), there was no significant difference in TLR [relative risk (RR): 1.02, 95% confidence interval (CI): 0.85-1.24; P = 0.80] or TVR (RR: 1.04, 95% CI: 0.81-1.34; P = 0.76). Safety outcomes of all-cause mortality, cardiac mortality, and MI were similar between the two groups. Stent thrombosis rates were also similar between BP-DES and DP-DES groups (1.66% vs. 1.83%; RR: 0.84, 95% CI: 0.54-1.31; P = 0.45). The heterogeneity was low and fixed-effect model yielded similar results. Meta-regression analysis showed no relationship between insulin requiring diabetes and difference in TLR or stent thrombosis between BP-DES and DP-DES. Conclusion Overall, BP-DESs have similar safety and efficacy profiles compared to contemporary DP-DES in patients with diabetes.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 50 条
  • [1] Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis
    Lv, Jianfeng
    Wu, Yazhou
    Zhang, Xingmei
    Jing, Tao
    Zhang, Li
    Tong, Shifei
    Song, Zhiyuan
    Wang, Mingli
    Wang, Gang
    Chi, Luxiang
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2015, 20
  • [2] Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis
    Jianfeng Lv
    Yazhou Wu
    Xingmei Zhang
    Tao Jing
    Li Zhang
    Shifei Tong
    Zhiyuan Song
    Mingli Wang
    Gang Wang
    Luxiang Chi
    European Journal of Medical Research, 20
  • [3] ARE BIODEGRADABLE POLYMER DRUG-ELUTING STENTS THE FUTURE? A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Gaddam, Sainath
    Nalluri, Nikhil
    Parikh, Valay
    Bhat, Tariq
    Tamburrino, Frank
    Lafferty, James
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A54 - A54
  • [4] Biodegradable polymer drug-eluting stents versus first-generation durable polymer drug-eluting stents A systematic review and meta-analysis of 12 randomized controlled trials
    Bundhun, Pravesh Kumar
    Pursun, Manish
    Huang, Feng
    MEDICINE, 2017, 96 (47)
  • [5] Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug- Eluting Stents
    El-Hayek, Georges
    Bangalore, Sripal
    Dominguez, Abel Casso
    Devireddy, Chandan
    Jaber, Wissam
    Kumar, Gautam
    Mavromatis, Kreton
    Tamis-Holland, Jacqueline
    Samady, Habib
    JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (05) : 462 - 473
  • [6] Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials
    Yake Lou
    Ying Yu
    Ziwei Xi
    Yanan Gao
    Wei Liu
    Xiaomin Nie
    Cardiovascular Drugs and Therapy, 2019, 33 : 557 - 566
  • [7] Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials
    Lou, Yake
    Yu, Ying
    Xi, Ziwei
    Gao, Yanan
    Liu, Wei
    Nie, Xiaomin
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (05) : 557 - 566
  • [8] Efficacy and safety of biodegradable polymer sirolimus-eluting stents versus durable polymer drug-eluting stents: A meta-analysis of randomized trials
    Yang, Yunjing
    Lei, Jiayan
    Huang, Wei
    Lei, Han
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 486 - 493
  • [9] Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis
    Kang, Si-Hyuck
    Park, Kyung Woo
    Kang, Do-Yoon
    Lim, Woo-Hyun
    Park, Kyung Taek
    Han, Jung-Kyu
    Kang, Hyun-Jae
    Koo, Bon-Kwon
    Oh, Byung-Hee
    Park, Young-Bae
    Kandzari, David E.
    Cohen, David J.
    Hwang, Seung-Sik
    Kim, Hyo-Soo
    EUROPEAN HEART JOURNAL, 2014, 35 (17) : 1147 - +
  • [10] Biodegradable-polymer drug-eluting stents Versus bare metal stents Versus durable-polymer drug-eluting stents in Patients With in Patients Undergoing Coronary Revascularization: a Meta-Analysis of Randomized Controlled Trials
    Zhu Jianbing
    Ge, Junbo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (16) : C169 - C170